InterMune

Brean Murray, Carret & Co., which initiated InterMune Inc. (NASDAQ: ITMN) at Buy, is providing some color on the stock. “We are initiating coverage of InterMune with a Buy rating and a $50 price target,” Brean Murray writes. “InterMune is beginning to launch Esbriet, a newly approved drug for...

JP Morgan has upgraded InterMune (NASDAQ: ITMN) from Neutral to Overweight and has raised the price target from $38 to $45.

JP Morgan has raised the price target on InterMune (NASDAQ: ITMN) from $32 to $38 and maintains its Neutral rating.

Wells Fargo is resuming coverage on InterMune, Inc.'s (NASDAQ: ITMN) with a change in analyst, a Market Perform rating, and a $13-$15 valuation range. “ITMN's lead drug, pirfenidone, produced mixed phase III results in idiopathic pulmonary fibrosis (IPF), with one study reaching its primary...

Shares of InterMune (NASDAQ: ITMN) were halted a short while ago pending news. More than likely it is related to their drug Esbriet(R) (pirfenidone), which is used to combat pulmonary fibrosis. Prior to the halting, the shares were down $5.41% to $45.44. Their were a few options trades today in the...

Thomas Weisel Partners analyst Stephen Willey maintained his Overweight rating for shares of InterMune, Inc. (Nasdaq: ITMN) and raised the price target from $26 to $55. The day before, a panel at the Food and Drug Administration recommended InterMune's pirfenidone for the treatment of idiopathic...

Shares of InterMune, Inc. (Nasdaq: ITMN) surged more than 60% after a panel at the Food and Drug Administration recommended the company's Esbriet for treatment of idiopathic pulmonary fibrosis. IPF is a rare and deadly lung disease with no existing FDA approved treatments, which affects nearly 200,...

Wells Fargo Securities analysts Aaron Reames and Matthew J. Andrews rated shares of InterMune, Inc. (Nasdaq: ITMN) Market Perform. The analysts questioned whether or not the FDA would accept InterMune's use of Forced Vital Capacity, as opposed to Overall Survival as the appropriate endpoint for the...